KRAS and neoplasm: Interestingly, using ACT of T cells specific for an MHC I epitope derived from mutated Kras controlled tumor growth in a patient with metastatic colorectal cancer (164) and is being further investigated preclinically (165) and via Kras-directed cancer vaccine trials (163).